Clinical trials: Graves' Ophthalmopathy
TED
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease
- Trial name
- NCT06769984
- Testing
- SCTT11
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Strabismus, Esotropia
Bupivacaine Injection of Eye Muscles to Treat Strabismus
This study seeks to determine if bupivacaine injection of eye muscles can make them stronger and stiffer, and thereby correct the position of eyes that are turned in or mis-aligned, a condition generally termed strabismus.
- Conditions
- Strabismus, Esotropia, Exotropia, Graves Disease
- Trial name
- NCT01616108
- Testing
- Bupivacaine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Smith-Kettlewell Eye Research Institute
Graves Disease
Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects
As the drug treatment of Graves' hyperthyroidism, Plummer reported the effectiveness of excess iodide in 1923 and iodide was used as the therapy for Graves' hyperthyroidism starting from the 1930s.
- Trial name
- NCT04686006
- Testing
- Potassium Iodide
- Volunteers
- 504 people
- Sponsor
- Kyushu University
Thyroid Eye Disease, Ocular Hypertension
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients.
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Trial name
- NCT01927406
- Testing
- Prostaglandin Analog, Timolol
- Where
- United States
- Sponsor
- Stanford University
Thyroid Orbitopathy
Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy
Background: The activity of thyroid orbitopathy can be evaluated with CAS (Clinical Activity Score) based on 7 inflammatory signs.
- Trial name
- NCT03891043
- Testing
- Selenium
- Volunteers
- 33 people
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Graves Disease
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
The purpose of this study is to assess the efficacy and safety of 24 weeks of treatment with batoclimab in adult participants with biochemically documented hyperthyroidism due to GD who have failed to achieve euthyroidism on…
- Trial name
- NCT05907668
- Testing
- IMVT-1401 (batoclimab)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Immunovant Sciences GmbH
Graves Disease, COVID-19
To Investigate the Effect of 2019 Novel Coronavirus Infection on the Condition of Patients With Hyperthyroidism
The goal of this observational study is to learn about the correlation between COVID-19 and hyperthyroidism in Patients with hyperthyroidism complicated with COVID-19.
- Trial name
- NCT06204393
- Testing
- Thyroid metabolic index
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Graves' Disease, Thyroid Disease
Shared Decision Making in Graves Disease - Graves Disease (GD) Choice
The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry…
- Conditions
- Graves' Disease, Thyroid Disease, Hyperthyroidism
- Trial name
- NCT02107794
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Mayo Clinic
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
- Trial name
- REVEAL-1 (NCT06625411)
- Testing
- VRDN-003
- Where
- 48 sites in United States, Germany and 3 more
- Volunteers
- 132 people
- Sponsor
- Viridian Therapeutics, Inc.
Graves Disease
Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.
- Trial name
- NCT01560299
- Testing
- Methimazole
- Where
- Iran
- Volunteers
- 150 people
- Sponsor
- Mashhad University of Medical Sciences
Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- STRIVE (NCT06384547)
- Testing
- Veligrotug
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 231 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Diseases
Preoperative Steroids in Autoimmune Thyroid Disease
This pilot project will randomize a small sample of patients about to undergo surgery for their autoimmune, inflammatory thyroid disease, and determine if a short course of prednisone alters the inflammation of the gland and…
- Trial name
- NCT04542278
- Testing
- Prednisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease.
- Trial name
- NCT07400757
- Testing
- Atorvastatin (Lipitor), Vitamin D
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Thyroid Eye Disease, TED
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease
- Trial name
- NCT06126783
- Testing
- IBI311
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypothyroidism, Exophthalmos
The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
Iodine 131 (131I） treatment on Graves disease and Graves ophthalmopathy relationship has always been the focus of debate. Majority view is that the current treatment does not increase 131I Graves ophthalmopathy, therefore,Graves…
- Trial name
- NCT01204359
- Testing
- Iodine 131
- Where
- 2 sites in China
- Volunteers
- 627 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
- Trial name
- spiriTED (NCT06088979)
- Testing
- TOUR006 - 20 MG, TOUR006 - 50 MG
- Where
- 36 sites in United States, Brazil and 9 more
- Volunteers
- 79 people
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
Graves' Disease
TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease
Graves' disease, the most common form of hyperthyroidism in children, is caused by Thyrotropin (TSH) Receptor Antibodies (TRAbs) that mimic the action of TSH.
- Trial name
- NCT00335062
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Boston Children's Hospital
Thyroid Eye Disease
Disappearance of Graves' Orbitopathy
There is a general belief among physicians involved with Graves' orbitopathy (GO) that this syndrome is somehow "chronic", namely that the patient's eyes do not return the way they were before GO appeared.
- Trial name
- DISGO (NCT03103607)
- Testing
- Ophthalmological evaluation, Questionnaire
- Volunteers
- 99 people
- Sponsor
- University of Pisa
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen
Graves Disease
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
The goal of this clinical trial is to compare two methods of guiding methimazole therapy in patients with Graves' disease: methimazole dose adjustments based on a new semi-automated computer-guided treatment (based on a…
- Trial name
- NCT06327828
- Testing
- Semi-automated computer-aided treatment (Digital Thyroid, DigiThy), Usual care
- Where
- Austria
- Volunteers
- 52 people
- Sponsor
- Medical University of Graz